CSL Limited Sponsored ADR (OTCMKTS:CSLLY – Get Free Report)’s share price traded down 0.5% during trading on Tuesday . The stock traded as low as $21.52 and last traded at $21.68. 796,933 shares changed hands during mid-day trading, an increase of 79% from the average daily volume of 445,994 shares. The stock had previously closed at $21.79.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on CSLLY. Jefferies Financial Group lowered shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Zacks Research cut shares of CSL from a “hold” rating to a “strong sell” rating in a report on Monday, May 11th. Finally, Citigroup cut shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce”.
Check Out Our Latest Analysis on CSL
CSL Stock Up 1.6%
CSL Company Profile
CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.
The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.
Further Reading
- Five stocks we like better than CSL
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
